105results about "Filtration" patented technology

The invention discloses a clean storage system for a household breathing machine. The machine body is provided with a breathing machine placing area, a storage device, an air purification system and a display control component, an air outlet is at least formed in the breathing machine placing area or the part, close to the breathing machine placing area, of the machine body, the storage device is provided with a storage chamber, an exhaust port and a storage port capable of being opened and closed, and the storage chamber is communicated with an air supply device. The air purification system is provided with a fan, an air purification device, an air outlet and an air inlet, an airflow channel in the machine body in the air outlet direction of the air purification device is a clean air area, the air outlet communicates with the airflow channel, the breathing machine containing area forms the clean air area, and the air supply device sucks clean air. The household breathing machine platform has a special platform space for placing various types of household breathing machines, has an air source filtering and purifying function, and has the advantages that accessories / parts of the household breathing machines can be cleanly stored, indoor environment air can be purified, and the like.

The embodiments disclose a method including bottling alcoholic beverages with selected ingredients including alcohol neutral spirits, alcohol and whisky, beer, wine, ingredients to add flavors and nutritional additive ingredients to benefit the health of an alcoholic beverage drinker, wherein a selection of alcohols includes vodka, tequila, gin, rum, brandy and other alcoholic spirits, wherein a selection of ingredients to add flavors includes flavorings including fruit flavorings, an artificial sweetener, and natural sweetener, wherein a selection of nutritional additive ingredients includes vitamins, minerals, fulvic acid, humic acid, ulmic acid and a purified and sanitized black water with humic acid and fulvic acid molecules in a mixed solution, and wherein bottling includes a bottling electronic monitoring, at least one control network, at least one bottling quality control process and a bottling labeling and packaging process and devices.

A convenience kit being formed by a pair of associated sub-kits which provide capability for bench-top medicine prescription compounding without need for clean room surroundings or such protective equipment as laminar flow hoods. The sub-kits include an exterior sub-kit which provides for access, volumetric measurement and compounding of medicine derived from vials and an enclosing sub-kit housed within a plastic bag which provides a sterile environment for filling a medical treatment vessel for use. The two sub-kits are joined together and communicate by bag entry technology to provide a system which not only protects and, in some cases, provides product sterility, but also assures full containment of all fluid being used in a medical preparation.

The invention discloses a recombinant III-type human collagen solution. The recombinant III-type human collagen solution comprises recombinant III-type human collagen, hyaluronic acid or salt thereof and a stabilizer, the stabilizer is selected from at least one of glycerol, butanediol, pentanediol, mannitol and trehalose. The compound system of the first stabilizer and the recombinant III-type human collagen can prevent the recombinant III-type human collagen from producing precipitates, and the compound system of the second stabilizer and the hyaluronic acid or the salt thereof is adopted to mix a first solution containing the recombinant III-type human collagen with a second solution containing the hyaluronic acid or the salt thereof, so that the recombinant III-type human collagen is obtained. According to the present invention, the recombinant human collagen can be prevented from generating flocculent precipitation or causing instability of the compounding system, and the recombinant human collagen has characteristics of good biocompatibility, good degradability, high stability, and particularly high thermal stability. Therefore, by adopting the recombinant III-type human collagen solution disclosed by the invention, wound healing and repairing can be promoted, healthy skin ecology can be reconstructed, and a new choice is provided for biomedical materials.

The invention discloses a filtering and antibacterial device for a hemodialyzer in nephrology, and specifically relates to the field of antibacterial disinfection of medical materials. The device comprises a main body mechanism, an auxiliary regulating mechanism is fixedly installed on the outer wall of the main body mechanism, a fluid channel mechanism is rotatably installed inside the main body mechanism, a plurality of dynamic filtering mechanisms are fixedly installed inside the fluid channel mechanism, and the fluid channel mechanism comprises a plurality of supporting layers, and the plurality of supporting layers are arranged in a superimposed state along the longitudinal center line direction thereof; the invention arranges a plurality of superimposed supporting layers, and arranges a guide tube and a spiral guide plate inside each supporting layer, so that a continuous vortex is formed when the dialysate flows through these spiral structures, thereby increasing the shear force of the fluid, thereby reducing the accumulation of impurities, avoiding the clogging of the filter holes, and reducing the probability of bacteria remaining in the impurities, thereby achieving a highly efficient physical antibacterial effect.

In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device.

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

A process for the preparation of sterile products comprising thermolabile and / or bioactive raw materials. The process comprises a step of sterilizing the products by filtration. Preferably, the sterile products obtained by the process are for cosmetic use, more preferably for use in cosmetic mesotherapy, such as anti-aging mesotherapy, or for medical use in aesthetic medicine or dermatology, preferably as injectable products. The process of the invention is particularly preferred for the preparation of sterile hyaluronic acids, or derivatives thereof.

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration. Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration.SOLUTION: Such formulations provide the theta defensin and / or theta defensin analog in a slightly acidic buffer containing propylene glycol. Surprisingly, the inventors have found that such formulations increase the bioavailability of θ-defensins and / or θ-defensin analogues so provided by at least a factor of 10 compared to conventional isotonic saline solutions, and dramatically improve bioavailability in human subjects compared to animal models. The inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, allowing reduced injection volumes and sterilization by simple filtration.SELECTED DRAWING: Figure 2

A purification device (2) for sterilizing and filtering intake air (4) is disclosed. The purification device (2) includes a housing (10) having a number of inlet holes (8) for allowing the intake air (4) to enter and a number of outlet holes (8') for allowing the air (6) purified by the purification device (2) to leave. The purification device (2) further includes a fan (12) disposed inside the housing (10) for drawing the intake air (4) into the housing (10) and blowing the purified air (6) out of the housing (10). The purification device (2) further includes an ultraviolet radiation lamp (14) disposed inside the housing (10) for irradiating the intake air (4). The purification device (2) further includes a high-efficiency particulate air (HEPA) filter (20) disposed to filter the intake air (4) before it leaves the housing (10) as purified air (6). The filter (20) has a plurality of pleats (32) arranged such that the angle (θ) between adjacent pleats (32) is 30° or less.

The present invention provides a pharmaceutical preparation in which an aqueous pharmaceutical composition, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, is housed in a packaging that blocks light rays of 210-380 nm in wavelength. In this pharmaceutical preparation, the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the aqueous pharmaceutical composition has been improved.

An injectable depot composition suitable for forming an in situ intramuscular implant is provided. The composition includes sterile biodegradable thermoplastic polymer of polylactic acid (PLA), solvent for the PLA, and drug. After administration to a subject, a corresponding implant administers 0.1-2 milligrams of nonsteroidal aromatase inhibitor every day throughout a dosing period of about six months to about one year. The composition is used to treat subjects in need thereof.

The embodiments disclose a method A method for manufacturing a black colored beverage, comprising purifying water safe for human consumption, mixing humic acid and fulvic acid into the purified water in a predetermined concentration to sufficiently suspend the humic acid and the fulvic acid within the water to imbue the purified water with a black color, mixing in the purified water with the suspended humic acid and fulvic acid at least one natural fruit flavoring and mixing a carbonation ingredient in the mixture of the at least one natural fruit flavoring and the suspended humic acid and the fulvic acid with the purified water.

A virus removal filtration device, comprising an air inlet device, a pressure reducing device, a pressure control module, a liquid storage device, a virus removal filter column and a collection device. A pressure reducing device and a pressure control module are connected to the pipeline between the air inlet device and the liquid storage device, and electromagnetic solenoid valves are respectively arranged on the pipelines of each liquid storage device; The control system of the virus removal filtration device includes a central processor and a display. The signal acquisition ends of the central processor are respectively connected to the signal output ends of a pressure sensor, a temperature sensor, a pressure sensor before the virus removal filter column and a weighing sensor, for collecting and processing the acquisition signals of each sensor; The signal output ends of the central processor are respectively connected to the signal input ends of the actuators of an automatic regulating valve and an electromagnetic solenoid valve. The device and system of the present invention can accurately control and regulate the pressure, and perform online and timely control on the virus removal filtration device.

In certain exemplary embodiments, an air purifier comprises a housing defining an enclosure and having an air entrance and an air exit; a particulate filter; a NCCO filter material configured to adsorb and decompose at least one gaseous pollutant; an AOG configured to generate at least one oxidant; an oxidant remover configured to remove at least one oxidant; a fan unit configured to generate airflow from the air entrance to the air exit; wherein the particulate filter, the NCCO filter material, the AOG, the oxidant remover and the fan unit are positioned within the enclosure such that during operation, a flow of air passes from the air entrance to the air exit through the particulate filter and the NCCO filter material along a direction of the flow of air. In certain embodiments, the air purifier may ensure safety to users while efficiency in removing contaminants can be greatly improved.

The present invention relates to a method for producing a sterile product containing heat labile and / or bioactive ingredients. The method includes a step of filter-sterilizing the product.Preferably, the sterile product obtained by the method of the invention is intended for cosmetic use, more preferably for use in cosmetic mesotherapy, such as anti-aging mesotherapy, or for medical use in aesthetic medicine or dermatology, preferably as an injectable.The method of the invention is particularly preferred for the production of sterile hyaluronic acid or its derivatives.

Disclosed is a clean storage system for a home ventilator, including a body with a ventilator placement region, storage device, air purification system, and display control component. Air outlets are at least formed in the ventilator placement region or a portion of the body proximal to the ventilator placement region. The storage device is provided with a storage chamber, exhaust ports, and a storage opening being opened or closed. The storage chamber communicates with an air supply device. The air purification system is provided with a fan, an air purification device, the air outlets, and air inlets. An airflow channel in an air outflow direction of the air purification device in the body is a clean air region, and the air outlets communicate with the airflow channel, such that a clean air area is formed in the ventilator placement region, and the air supply device draws in clean air.

The present invention relates to a method for sterile filtration of an albumin-containing aqueous solution (2), wherein the method comprises filtering the solution (2) with at least one filter (3) to obtain a filtrate (1), wherein the at least one filter (3) is conditioned prior to filling the filtrate (1) into at least one container (10, 10') by purging the at least one filter (3) with a quantity (5) of the albumin-containing aqueous solution (2) i) at a differential pressure across the respective filter (3) of at most 1 bar and / or ii) by means of pressure filtration, wherein the filtrate (1) is maintained in the outlet (4) of the respective filter (3) at a back pressure of at least 0.5 bar is maintained.

The invention provides a mannitol injection and a production method thereof, which are characterized in that the dissolution and stability treatment of mannitol is improved, and the safety and effectiveness of a final product are enhanced. The preparation method comprises the following specific steps: firstly, mixing and dissolving mannitol and cyclodextrin according to a certain proportion, and forming a compound through a freeze-drying technology so as to improve the stability of a solution; then, adding a proper amount of electrolyte and an acid-base regulator to adjust the pH value so as to optimize physiological compatibility and reduce local stimulation; then, the purity and sterility of the solution are ensured through a double filtration system; and finally, high-temperature sterilization is adopted to ensure the sterility of the product. The series of processes not only improve the bioavailability of the mannitol injection, but also significantly reduce the complexity and risk caused by crystal precipitation, so that the product is more suitable for wide application in the medical field, such as treatment of encephaledema or reduction of intracranial pressure.

The present invention relates to a method for the sterile filtration of an aqueous albumin-containing solution (2), where the method comprises filtering the solution (2) with at least one filter (3) to obtain a filtrate (1), where the filtrate (1) is filled in at least one container (10, 10 ') before the filtrate (1) is filled in the at least one container (10, 10'), the at least one container (10, 10 ') is filled in the at least one container (10, 10'). The at least one filter (3) is conditioned by washing the at least one filter (3) with an amount (5) of the albumin-containing aqueous solution (2) under the following conditions: i) at a differential pressure across the respective filter (3) of at most 1 bar and / or ii) by means of pressure filtration, wherein the filtrate (1) is maintained at a back pressure of at least 0.5 bar in the outlet (4) of the respective filter (3).

The present invention provides a kind of favipiravir solution for atomized inhalation, preparation method and application. The inhalation solution contains 1-50mg / ml favipiravir, excipients and solvent in a single dose, and the pH value is 5.5-9.0, and the inhalation solution single dose specification is 2-5ml. The excipients include a cosolvent, a pH regulator and an osmotic pressure regulator. The cosolvent is selected from meglumine, and the mass ratio of favipiravir to meglumine is 1:1.25-1:1.34, and the pH regulator can be selected from sodium dihydrogen phosphate, disodium hydrogen phosphate, and one or more of potassium dihydrogen phosphate, the osmotic pressure regulator is selected from sodium chloride, and the solvent is selected from sterile water for injection. The solution of favipiravir can be used in combination with a liquid atomizer to provide a convenient, safe, effective and stable pharmaceutical dosage form and drug delivery system of favipiravir.

The present disclosure provides compositions and methods for inactivating lipid-enveloped viruses in product feedstreams in therapeutic protein manufacturing processes using environmentally compatible surfactants. The present invention provides a surfactant mixture that includes two environmentally sustainable surfactants, n-octyl-β-D-glucopyranoside (OG) and n-dodecyl-β-D-maltopyranoside (DDM). The performance of this OG:DDM surfactant combination has been compared to lauryl dimethylamine oxide (LDAO), ECOSURF, and EDTA in the purification of therapeutic proteins such as abatacept and belatacept. (商標) EH9, or Triton X-100. The OG:DDM combination is highly effective at viral inactivation, but has essentially no effect on protein stability, protein charge distribution (e.g., sialic acid levels), impurity clearance, protein deamination, or protein oxidation. Thus, the OG and DDM combination can be used as an alternative to Triton X-100 for the viral inactivation step in the manufacturing of biologics.

An apparatus (1) for applying a coating to an injection medical device, comprising a feed tank (10) loadable with a coating substance, an output nozzle (80) for delivering the coating substance to the injection medical device, and a supply assembly (20) interposed between and in fluid communication with the feed tank (10) and the output nozzle (80) for removing the coating substance from the feed tank (10) and supplying it to the output nozzle (80). The supply assembly (20) comprises at least one sterilizing filter (30a, 30b) for filtering the coating substance removed from the feed tank (10).

A method for preparing a filtered beverage includes filtering a raw beverage using a cross-flow ultrafiltration device to produce a solids fraction and a liquid fraction; heating the solids fraction to a temperature of 60° C. or greater to produce a pasteurized solids fraction; microfiltering the liquid fraction through a microfilter having a size cut-off of 1 μm or smaller to produce a microfiltered liquid fraction; and combining the pasteurized solids fraction and the microfiltered liquid fraction to result in the filtered beverage.

In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device.

This paper describes a method for producing a sterile in-situ gel based on solvent removal technology, and the resulting product. Compared to conventional aseptic manufacturing methods for in-situ gel formulations, this method adds a volatile solvent during production to reduce the viscosity of the formulation solution, facilitating filtration and sterilization. The volatile solvent can then be removed by various methods without adversely affecting the final in-situ gel formulation. Research data shows that the volatile solvent residues in in-situ gel formulations produced using this method meet safety standards. Compared to formulations produced using the conventional radiation sterilization method, the types and amounts of degradation impurities in the polymer and active pharmaceutical ingredients are both reduced, further improving the safety of the formulation.

An injectable depot composition suitable for forming an in situ intramuscular implant is provided. The composition includes sterile biodegradable thermoplastic polymer of polylactic acid (PLA), solvent for the PLA, and drug. After administration to a subject, a corresponding implant administers 0.1-2 milligrams of nonsteroidal aromatase inhibitor every day throughout a dosing period of about six months to about one year. The composition is used to treat subjects in need thereof.

The invention relates to a method for inactivating an enveloped virus in a biopharmaceutical-containing fluid, said method comprising exposing said fluid to a substituted cyclodextrin. The invention also relates to a method for purifying and / or producing a biopharmaceutical comprising exposing a biopharmaceutical-containing fluid to a substituted cyclodextrin.

A drug production facility includes: a first module comprising drug substance and drug product manufacturing equipment including equipment for producing RNA-based drug substance, lipid nanoparticle (LNP)-based drug products and lipoplex-based drug products; and a second module that includes fill and finish process equipment.